Transfused B19V: B-nign, B-ware, B-gone?

Blood

Volumn 114, Issue 17, 2009, Pages 3509-3511

  Klein, Harvey G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; DNA DETERMINATION; INFECTION RISK; NOTE; PARVOVIRUS; PRIORITY JOURNAL; SCREENING;

EID: 70449496686     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-239939     Document Type: Note

References (7)

1. Kleinman SH, Glynn SA, Lee T-H, et al. A linked donor-recipient study to evaluate B19 transmission by blood component transfusion. Blood. 2009;114(17):3677-3683.
2. Young NS, Brown KE. Parvovirus B19.NEngl J Med. 2004;350(6):586-597.
3. Brown KE, Young NS, Alving BM, Barbosa LH. Parvovirus B19: implications for transfusion medicine: summary of a workshop. Transfusion. 2001;41(1):130-135.
4. Kleinman SH, Glynn SA, Lee TH, et al. Prevalence and quantitation of parvovirus B19DNAlevels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion. 2007;47(10):1756-1764.
5. Lefrère JJ, Servant-Delmas A, Candotti D, et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood. 2005; 106(8):2890-2895.
6. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion. 2000;40(10): 1203-1206. (Pubitemid 30782915)
7. Draft guidance for industry: nucleic acid testing (NAT) to reduce the possible risk of parvovirus B19 transmission by plasma-derived products. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatory Information/Guidances/Blood/ucm071592.htm. Published January 29, 2009. Accessed August 31, 2009.